HC
LFCR icon

Hurley Capital’s Lifecore Biomedical LFCR Stock Holding History

Hurley Capital’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,148
Closed -$4.27K – 696
2026
Q1 		$4.27K Buy
+1,148
New +$7.93K ﹤0.01% 470
2025
Q2 		– Sell
-5,000
Closed -$35.2K – 484
2025
Q1 		$35.2K Buy
+5,000
New +$31.1K 0.03% 206

Other funds holding LFCR

WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

Hurley Capital's LFCR Position: Q2 2026 in Review

Hurley Capital sold out of Lifecore Biomedical (LFCR) in Q2 2026, closing a stake of 1,148 shares — an estimated $4.27K sold.

Hurley Capital first reported a position in LFCR in Q1 2025 and held it in 2 quarters. The position peaked at $35.2K in Q1 2025. 98 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • Hurley Capital reported no remaining Lifecore Biomedical position as of Q2 2026 after selling out during the quarter.
  • Hurley Capital sold 1,148 Lifecore Biomedical shares in Q2 2026, an estimated $4.27K.
  • Hurley Capital first reported a position in Lifecore Biomedical in Q1 2025 and held it in 2 quarters.
  • Hurley Capital's Lifecore Biomedical position peaked at $35.2K in Q1 2025.
  • 98 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on Hurley Capital's 13F filing for Q2 2026, filed 10 Aug 2026.